Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality, with portal vein tumor thrombosis (PVTT) being a common complication that significantly worsens prognosis. Recent
Assessment of safety and toxicity, definition of the dose limiting toxicity (DLT) of the combination therapy consisting of Capecitabine, Oxaliplatin, Bevacizumab and Imatinib.
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related mortality, with portal vein tumor thrombosis (PVTT) being a common complication that significantly worsens prognosis. Recent